Filter Results:
(699)
Show Results For
- All HBS Web
(1,190)
- People (1)
- News (316)
- Research (699)
- Events (5)
- Multimedia (14)
- Faculty Publications (418)
Show Results For
- All HBS Web
(1,190)
- People (1)
- News (316)
- Research (699)
- Events (5)
- Multimedia (14)
- Faculty Publications (418)
Sort by
- March 2010 (Revised January 2011)
- Case
Carrot or Stick? Getting Paid for Innovation at Tessera Technologies
By: Willy C. Shih
Tessera Technologies has been very successful developing technologies for the semiconductor and mobile device industry, and then licensing them broadly to manufacturers. In addition to licensing patents, it also supplies know-how to help manufacturers move into... View Details
Keywords: Business Model; Innovation Strategy; Patents; Courts and Trials; Rights; Mobile Technology; Semiconductor Industry; California
Shih, Willy C. "Carrot or Stick? Getting Paid for Innovation at Tessera Technologies." Harvard Business School Case 610-085, March 2010. (Revised January 2011.)
- 07 Jun 2017
- Research & Ideas
How an African History Scholar Became a Modern Righter of Wrongs
Leigh Day—and six decades after the Kenyan rebels were detained and tortured, the British government settled out of court with some 5,500 Kikuyu detention camp survivors. The monetary payout was 19.9 million... View Details
Keywords: by Carmen Nobel
- August 2008 (Revised May 2009)
- Background Note
International Enforcement of U.S. Patents
By: Robert C. Pozen and Jordan Hirsch
A company that owns a U.S. patent can enforce its patent protections in three ways: by filing a lawsuit in U.S. federal district court, by bringing action in the International Trade Commission, or through the World Trade Organization. This note discusses the pros and... View Details
Pozen, Robert C., and Jordan Hirsch. "International Enforcement of U.S. Patents." Harvard Business School Background Note 309-022, August 2008. (Revised May 2009.)
- 02 Jun 2011
- Research & Ideas
Signing at the Top: The Key to Preventing Tax Fraud?
end of the tax form, after the form has been filled out and, consequently, after the potential cheating has occurred. (It's analogous to a witness first testifying in a court trial View Details
- September 2017 (Revised February 2018)
- Case
Becton Dickinson: Global Health Strategy
By: Mark R. Kramer and Sarah Mehta
Becton, Dickinson and Company (BD) was a medical technology firm headquartered in Franklin Lakes, New Jersey, with 43,000 employees and 2016 revenues of $12.5 billion. For several years, the company had pursued developing products that created shared value, defined as... View Details
Keywords: Shared Value; Creating Shared Value; Odon Device; Medical Technology; Value Creation; Values and Beliefs; Philanthropy and Charitable Giving; Health; Health Care and Treatment; Health Testing and Trials; Emerging Markets; Social Issues; Competitive Strategy; Medical Devices and Supplies Industry; Africa; Asia; Middle East
Kramer, Mark R., and Sarah Mehta. "Becton Dickinson: Global Health Strategy." Harvard Business School Case 718-406, September 2017. (Revised February 2018.)
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
the anatomical—basis of the disease." Genzyme, which currently has drugs in clinical trials for melanoma and breast cancer, hopes to have its first products on the market as early as 2004. "I think... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- September 2008
- Background Note
Background on the Technology of Molecular Diagnostics
By: Regina E. Herzlinger and Jason Sanders
To be used as background reading for the "EXACT Sciences Corp.: Commercializing a Diagnostic Test" and "Diagnostic Genomics" cases, HBS nos. 308-090 and 309-040. View Details
Keywords: Health Testing and Trials; Technology; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry
Herzlinger, Regina E., and Jason Sanders. "Background on the Technology of Molecular Diagnostics." Harvard Business School Background Note 309-050, September 2008.
- July 2003 (Revised February 2004)
- Background Note
M&A Legal Context: Standards Related to the Sale or Purchase of a Company
By: Carliss Y. Baldwin, Constance E. Bagley and James Quinn
Introduces students to the legal standards affecting officers and directors when selling or purchasing a company. Provides a practical understanding of the Revlon Standard, the Securities and Exchange Act of 1934, Rule 10b-5, and the legal criteria for a cause of... View Details
Keywords: Laws and Statutes; Law Enforcement; Government Legislation; Acquisition; Business Exit or Shutdown; Corporate Governance; Going Public; Courts and Trials
Baldwin, Carliss Y., Constance E. Bagley, and James Quinn. "M&A Legal Context: Standards Related to the Sale or Purchase of a Company." Harvard Business School Background Note 904-004, July 2003. (Revised February 2004.)
- 18 Jun 2014
- Research & Ideas
Book Excerpt: ‘Collective Genius’
organizational context, with the right leadership, a group can amplify the diverse talents and ideas of its individual members. Leaders Foster Discovery-driven Learning Innovation usually arises from an often lengthy period of conscious... View Details
- December 2021
- Case
Should I Stay or Should I Go? Assessing Risk in Carlos Ghosn's International Escape
By: Eugene F. Soltes, Grace Liu and Muneeb Ahmed
In 2018, automotive tycoon Carlos Ghosn was arrested in Japan on financial misreporting charges, followed later by charges of improper payments and misappropriation of funds. Over a year later, still awaiting trial, Ghosn organized his escape from house arrest in Tokyo... View Details
Keywords: Crime and Corruption; Decision Making; Cost vs Benefits; Decision Choices and Conditions; Ethics; Cross-Cultural and Cross-Border Issues; Law; Courts and Trials; Rights; Risk and Uncertainty; Auto Industry; Japan
Soltes, Eugene F., Grace Liu, and Muneeb Ahmed. "Should I Stay or Should I Go? Assessing Risk in Carlos Ghosn's International Escape." Harvard Business School Case 122-051, December 2021.
- October 2019 (Revised April 2020)
- Background Note
Note on Funding Deep Tech Startups
By: Karim Lakhani, Peter Barrett and Noubar Afeyan
This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along... View Details
Keywords: Entrepreneurship; Energy; Venture Capital; Corporate Finance; Initial Public Offering; Investment; Health Testing and Trials; Innovation and Invention; Technological Innovation; Intellectual Property; Product Design; Product Development; Information Technology; Research and Development; Risk and Uncertainty; Technology Industry; Biotechnology Industry; United States; North America; Europe; Asia
Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
- December 2014 (Revised August 2015)
- Case
Improving Melanoma Screening: MELA Sciences
By: Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols
MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and... View Details
- March 30, 2020
- Article
Why Is the U.S. Behind on Coronavirus Testing?
By: Stefan Thomke
Coronavirus testing is needed to address the uncertainty in making decisions about patient treatment, resource allocation, policy, and so much more. Answers to questions such as “When should we relax social distancing measures—and for whom?” or “How many ventilators... View Details
Keywords: Testing; Coronavirus; Culture; Trump; Data; Experiments; Health Pandemics; Health Testing and Trials; Government and Politics; United States
Thomke, Stefan. "Why Is the U.S. Behind on Coronavirus Testing?" Harvard Business Review Digital Articles (March 30, 2020).
- January 2011 (Revised March 2011)
- Case
Predictive Biosciences
By: Thomas R. Eisenmann, Jeffrey J. Bussgang and David Kiron
A small cancer diagnostics start-up is deciding whether to acquire a laboratory to make and sell its bladder cancer test or build its own manufacturing and sales team. View Details
Keywords: Mergers and Acquisitions; Factories, Labs, and Plants; Business Startups; Entrepreneurship; Health Testing and Trials; Growth and Development Strategy; Product Development; Biotechnology Industry
Eisenmann, Thomas R., Jeffrey J. Bussgang, and David Kiron. "Predictive Biosciences." Harvard Business School Case 811-015, January 2011. (Revised March 2011.)
- 26 Jun 2000
- Research & Ideas
What’s an Internet Business Model? Ask a Health Care Professional
out how to get into a clinical trial to try an experimental drug. For their part, physicians are often befuddled by difficult cases that don't respond to traditional therapies. And pharmaceutical companies,... View Details
- February 2020
- Supplement
Theranos: Who Has Blood on Their Hands? (B)
By: Nien-he Hsieh, Christina R. Wing and John Masko
This supplemental case tracks the results of the Colman and Taubman-Dye class action suit against Theranos as well as Theranos’ other legal challenges and chronicles the final demise of the company in 2019. View Details
Keywords: Health Testing and Trials; Corporate Accountability; Organizational Culture; Misleading and Fraudulent Advertising; Crime and Corruption; Entrepreneurship; Lawsuits and Litigation; Business Exit or Shutdown; Medical Devices and Supplies Industry; California; United States
Hsieh, Nien-he, Christina R. Wing, and John Masko. "Theranos: Who Has Blood on Their Hands? (B)." Harvard Business School Supplement 320-091, February 2020.
- 2003
- Chapter
La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971
By: Arthur A. Daemmrich
- December 2023 (Revised March 2024)
- Case
Manufacturing Moderna's Future
By: Satish Tadikonda and William Marks
In 2019, Moderna faced long odds of survival having failed to develop a successful clinical program out of the vast platform technology they had built around mRNA. Nearly overnight, the company skyrocketed to success with a vaccine for COVID-19, leading to an extremely... View Details
Keywords: Health Pandemics; Health Testing and Trials; Technological Innovation; Product Development; Production; Science-Based Business; Biotechnology Industry
Tadikonda, Satish, and William Marks. "Manufacturing Moderna's Future." Harvard Business School Case 824-076, December 2023. (Revised March 2024.)